In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli

Suzannah M. Schmidt-Malan, Avisya J. Mishra, Ammara Mushtaq, Cassandra L. Brinkman, Robin Patel

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel -lactam–-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli. For isolates harboring blaKPC (n 110), the addition of relebactam to imipenem lowered the MIC50/MIC90 from 16/ 128 g/ml for imipenem alone to 0.25/1 g/ml. For isolates harboring blaCTX-M (n 48), the MIC50/MIC90 of ceftolozane-tazobactam were 0.5/16 g/ml (83% susceptible). For isolates harboring blaCMY-2 (n 17), the MIC50/MIC90 of ceftolozane-tazobactam were 4/8 g/ml (47% susceptible). Imipenem-relebactam was active against most KPC-producing (but not NDM- or IMP-producing) Enterobacteriaceae and is an encouraging addition to the present antibiotic repertoire.

Original languageEnglish (US)
Article numbere00533-18
Pages (from-to)1DUMMY
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Imipenem
Bacillus
meropenem
Lactams
Inosine Monophosphate
Ceftriaxone
Enterobacteriaceae
Anti-Infective Agents
tazobactam drug combination ceftolozane
In Vitro Techniques
MK-7655
Anti-Bacterial Agents
Pharmaceutical Preparations

Keywords

  • Antimicrobial resistance
  • Gram-negative bacilli

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli. / Schmidt-Malan, Suzannah M.; Mishra, Avisya J.; Mushtaq, Ammara; Brinkman, Cassandra L.; Patel, Robin.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 8, e00533-18, 01.08.2018, p. 1DUMMY.

Research output: Contribution to journalArticle

Schmidt-Malan, Suzannah M. ; Mishra, Avisya J. ; Mushtaq, Ammara ; Brinkman, Cassandra L. ; Patel, Robin. / In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli. In: Antimicrobial Agents and Chemotherapy. 2018 ; Vol. 62, No. 8. pp. 1DUMMY.
@article{c8bc2bd1173f481eaa71acfef2bc02fb,
title = "In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli",
abstract = "Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel -lactam–-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli. For isolates harboring blaKPC (n 110), the addition of relebactam to imipenem lowered the MIC50/MIC90 from 16/ 128 g/ml for imipenem alone to 0.25/1 g/ml. For isolates harboring blaCTX-M (n 48), the MIC50/MIC90 of ceftolozane-tazobactam were 0.5/16 g/ml (83{\%} susceptible). For isolates harboring blaCMY-2 (n 17), the MIC50/MIC90 of ceftolozane-tazobactam were 4/8 g/ml (47{\%} susceptible). Imipenem-relebactam was active against most KPC-producing (but not NDM- or IMP-producing) Enterobacteriaceae and is an encouraging addition to the present antibiotic repertoire.",
keywords = "Antimicrobial resistance, Gram-negative bacilli",
author = "Schmidt-Malan, {Suzannah M.} and Mishra, {Avisya J.} and Ammara Mushtaq and Brinkman, {Cassandra L.} and Robin Patel",
year = "2018",
month = "8",
day = "1",
doi = "10.1128/AAC.00533-18",
language = "English (US)",
volume = "62",
pages = "1DUMMY",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli

AU - Schmidt-Malan, Suzannah M.

AU - Mishra, Avisya J.

AU - Mushtaq, Ammara

AU - Brinkman, Cassandra L.

AU - Patel, Robin

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel -lactam–-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli. For isolates harboring blaKPC (n 110), the addition of relebactam to imipenem lowered the MIC50/MIC90 from 16/ 128 g/ml for imipenem alone to 0.25/1 g/ml. For isolates harboring blaCTX-M (n 48), the MIC50/MIC90 of ceftolozane-tazobactam were 0.5/16 g/ml (83% susceptible). For isolates harboring blaCMY-2 (n 17), the MIC50/MIC90 of ceftolozane-tazobactam were 4/8 g/ml (47% susceptible). Imipenem-relebactam was active against most KPC-producing (but not NDM- or IMP-producing) Enterobacteriaceae and is an encouraging addition to the present antibiotic repertoire.

AB - Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel -lactam–-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli. For isolates harboring blaKPC (n 110), the addition of relebactam to imipenem lowered the MIC50/MIC90 from 16/ 128 g/ml for imipenem alone to 0.25/1 g/ml. For isolates harboring blaCTX-M (n 48), the MIC50/MIC90 of ceftolozane-tazobactam were 0.5/16 g/ml (83% susceptible). For isolates harboring blaCMY-2 (n 17), the MIC50/MIC90 of ceftolozane-tazobactam were 4/8 g/ml (47% susceptible). Imipenem-relebactam was active against most KPC-producing (but not NDM- or IMP-producing) Enterobacteriaceae and is an encouraging addition to the present antibiotic repertoire.

KW - Antimicrobial resistance

KW - Gram-negative bacilli

UR - http://www.scopus.com/inward/record.url?scp=85052017885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052017885&partnerID=8YFLogxK

U2 - 10.1128/AAC.00533-18

DO - 10.1128/AAC.00533-18

M3 - Article

C2 - 29760145

AN - SCOPUS:85052017885

VL - 62

SP - 1DUMMY

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

M1 - e00533-18

ER -